Eric Schmidt

Michael Schmidt

Rajan Sharma

Jack Allen

Jonathan Chang

Justin Zelin

Naureen Quibria

Tyler Van Buren

Elias Lenard

Michael Yee

Patrick Trucchio

Peter Lawson

Ahu Demir

Avantika Joshi

Ethan Markowski

Gil Blum

Graig Suvannavejh

Adam Ferrari

Albert Agustinus

David Dai

James Shin

Jeff Jones

Jeffrey Hung

Jeffrey Jones

Jessica Fye

Paul Jeng

Romeo O'Connor

Sean Laaman

Xiaochuan Dai

- Immunocore's product, **KIMMTRAK**, generated **$192 million** in the first half of this year, representing a **32% growth rate** over the same period last year, with future growth expected to moderate to **4%-7% quarterly sequential growth** as the product matures in its current indication.  **[1671927_2137445_2]** 
- The company is advancing **three Phase III trials** for pipeline expansion: **TEBI-AM** (advanced cutaneous melanoma) with enrollment completing in **H1 2026** and data expected in **H2 2026**, **ADAM** (adjuvant uveal melanoma) with a **three-year enrollment** period, and **PRISM-mel** (first-line cutaneous melanoma) with a dose selection triggered after **90 patients**.  **[1671927_2137445_3]** **[1671927_2137445_4]** **[1671927_2137445_5]** 
- Immunocore maintains a **robust balance sheet** with almost **$900 million of cash**, enabling it to fund its pipeline for the foreseeable future, despite expected increases in R&D investments due to the ongoing Phase III trials.  **[1671927_2137445_7]**

Immunocore Holdings Discusses KIMMTRAK Performance and Pipeline Advancement

- Immunocore's lead product, **KIMMTRAK**, generated **$192 million** in the first half of 2025, representing **32% growth** over the same period last year.  **[1671927_2137431_3]**  While growth in its current indication is expected to **moderate** to **4% to 7% quarterly sequential growth**, the company is pursuing two Phase III trials for lifecycle management: TEBI-AM for advanced cutaneous melanoma (data expected **H2 2026**) and ADAM for adjuvant uveal melanoma.  **[1671927_2137431_3]** **[1671927_2137431_5]** 
- The company maintains a **robust balance sheet** with almost **$900 million in cash**, enabling it to fund its pipeline for the foreseeable future.  **[1671927_2137431_7]**  Immunocore anticipates increased R&D investments due to three ongoing Phase III trials, while maintaining discipline in SG&A, which has been flat at around **$40 million to $42 million per quarter**.  **[1671927_2137431_7]** 
- Beyond KIMMTRAK, Immunocore is advancing its **PRAME franchise** with a Phase III study (PRISM-mel) in **first-line cutaneous melanoma** and other efforts, with data and next steps expected within the **next 12 months**.  **[1671927_2137431_5]**  Early-stage pipeline includes infectious disease programs (HBV data later this year) and autoimmune programs (Type 1 diabetes CTA by **end of 2025**, CD1A CTA/IND in **2026**).  **[1671927_2137431_5]** **[1671927_2137431_6]**

Immunocore Holdings Provides Business Update at Morgan Stanley Global Healthcare Conference

Immunocore Holdings (IMCR)